Zacks Research Has Strong Forecast for PBH FY2026 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Investment analysts at Zacks Research boosted their FY2026 earnings per share estimates for shares of Prestige Consumer Healthcare in a research note issued on Monday, July 14th. Zacks Research analyst R. Department now expects that the company will post earnings of $4.74 per share for the year, up from their previous forecast of $4.73. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share.

PBH has been the subject of a number of other reports. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Price Performance

NYSE:PBH traded up $0.57 during trading hours on Thursday, reaching $75.70. The company had a trading volume of 419,148 shares, compared to its average volume of 316,814. The stock has a 50-day moving average of $82.92 and a two-hundred day moving average of $82.29. Prestige Consumer Healthcare has a one year low of $64.94 and a one year high of $90.04. The firm has a market capitalization of $3.74 billion, a PE ratio of 17.65, a PEG ratio of 2.27 and a beta of 0.43. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. The company had revenue of $296.52 million during the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.02 earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. UMB Bank n.a. boosted its stake in shares of Prestige Consumer Healthcare by 81.8% during the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company's stock worth $26,000 after acquiring an additional 144 shares during the period. Maseco LLP bought a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $27,000. CIBC Private Wealth Group LLC boosted its stake in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares during the period. Opal Wealth Advisors LLC bought a new position in shares of Prestige Consumer Healthcare during the 1st quarter worth approximately $38,000. Finally, Headlands Technologies LLC bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $40,000. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.